Feasibility study of human umbilical cord tissue-derived mesenchymal stem cells in patients with multiple sclerosis
Overview:
The purpose of this phase 1 study being conducted by the Stem Cell
Institute in Panama is to assess the safety and effectiveness of
donor (allogeneic) umbilical cord mesenchymal stem cells (MSC’s)
administered to patients with multiple sclerosis (MS). The study
commenced in January 2014 and aims to recruit 20 patients between
the age of 18 and 55 years with MS. Participants will receive an
intravenous injection of MSC’s once a day for 7 days and will be
followed up after treatment to determine the therapeutic effect at
4, 12 and 52 weeks. Participants will be evaluated post treatment by
neurological assessments: walking time, quality of life survey, and
MRI scans of the brain and cervical (neck region) spinal cord. The
estimated completion date is August 2017.
Location: Panama City, Panama
Trial design: Safety and efficacy
Status: Recruiting
Find out more